Literature DB >> 6474101

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.

D W Heinrichs, T E Hanlon, W T Carpenter.   

Abstract

There is growing interest in deficit symptoms in studies of the course and treatment response of schizophrenia. However, existing clinical assessment instruments focus primarily on productive symptoms. The authors describe the Quality of Life Scale (QLS), a 21-item scale based on a semistructured interview designed to assess deficit symptoms and thereby fill an important gap in the range of instruments now available. Data regarding reliability and training in the use of the QLS are presented. A factor analysis of the items yields results compatible with the conceptual model on which the scale is based. The factor analysis was also performed separately by sex and was fundamentally similar for men and women.

Entities:  

Mesh:

Year:  1984        PMID: 6474101     DOI: 10.1093/schbul/10.3.388

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  373 in total

1.  Refining quality of life: validating a multidimensional factor measure in the severe mentally ill.

Authors:  S L Bishop; D P Walling; S G Dott; C C Folkes; J Bucy
Journal:  Qual Life Res       Date:  1999       Impact factor: 4.147

Review 2.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

3.  An evaluation of psychometric properties of the client's questionnaire of the Wisconsin Quality of Life Index-Canadian version (CaW-QLI).

Authors:  P Diaz; C Mercier; R Hachey; J Caron; G Boyer
Journal:  Qual Life Res       Date:  1999-09       Impact factor: 4.147

4.  Current status of quality of life assessment in schizophrenic patients.

Authors:  J Bobes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

5.  Measuring subjective quality of life in people with serious mental illness using the SEIqoL-DW.

Authors:  P N Prince; G J Gerber
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

Review 6.  Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?

Authors:  Azizah Attard; David M Taylor
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

7.  Measurement of quality of life in schizophrenia: a comparison of two scales.

Authors:  Yvette Kusel; Richard Laugharne; Sian Perrington; Jan McKendrick; Deborah Stephenson; J Stockton-Henderson; Madeline Barley; R McCaul; Tom Burns
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-08-29       Impact factor: 4.328

Review 8.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

9.  Measuring motivation in schizophrenia: is a general state of motivation necessary for task-specific motivation?

Authors:  Jimmy Choi; Kee-Hong Choi; L Felice Reddy; Joanna M Fiszdon
Journal:  Schizophr Res       Date:  2014-02-12       Impact factor: 4.939

10.  Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.

Authors:  Deepak C D'Souza; Rajiv Radhakrishnan; Edward Perry; Savita Bhakta; Nagendra M Singh; Richa Yadav; Danielle Abi-Saab; Brian Pittman; Santosh K Chaturvedi; Mahendra P Sharma; Morris Bell; Chittaranjan Andrade
Journal:  Neuropsychopharmacology       Date:  2012-10-24       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.